Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1988;27(1):69-76.
doi: 10.1007/BF00205761.

Proliferative response of lymphocytes from ovarian cancer patients to autologous tumor cells

P Allavena  1 , P Lo Presti, M Di Bello, V Lucchini, A Lissoni, G Zanetta, C Mangioni, A Mantovani
Affiliations

Proliferative response of lymphocytes from ovarian cancer patients to autologous tumor cells

P Allavena et al. Cancer Immunol Immunother. 1988.

Abstract

Peripheral blood lymphocytes (PBL) from 43 patients with histologically confirmed ovarian carcinoma were stimulated in mixed lymphocyte-tumor culture (MLTC) with purified autologous tumor cells. Positive results, assessed as lymphocyte proliferation, were observed in 21 cases (48.8%). Lymphoid cells associated with ascitic fluid or infiltrating solid masses were in general less reactive than PBL as only 3/11 cases had positive MLTC. Tumor cells isolated from peritoneal effusions showed no significant difference in stimulatory potential as compared to the primary tumor. These results suggest that in an appreciable proportion of ovarian carcinoma patients (approximately 50%), lymphocytes have the potential to react to autologous tumor cells. Comprehension of the immunological mechanisms of antitumor resistance may have direct practical relevance for more effective treatment of neoplasms.

PubMed Disclaimer

References

    1. Akiyama M, Bean MA, Sadamoto K, Takahashi Y, Brankovan V. Suppression of the responsiveness of lymphocytes from cancer patients triggered by co-culture with autologous tumor-derived cells. J Immunol. 1983;131:3085. - PubMed
    1. Allavena P, Introna M, Sessa C, Mangioni C, Mantovani A. Interferon effect on cytotoxicity of peripheral blood and tumor-associated lymphocytes against human ovarian carcinoma cells. J Natl Cancer Inst. 1982;68:555. - PubMed
    1. Allavena P, Zanaboni F, Rossini S, Merendino A, Bonazzi C, Vassena L, Mangioni C, Mantovani A. Lymphokine-activated killer activity of tumor-associated and peripheral blood lymphocytes isolated from patients with ascites ovarian tumors. J Natl Cancer Inst. 1986;77:863. - PubMed
    1. Berek JS, Bast RC, Jr, Lichtenstein A, Hacker NF, Spina CA, Lagasse LD, Knapp RC, Zighelboim J. Lymphocyte cytotoxicity in the peritoneal cavity and blood of patients with ovarian cancer. Obstet Gynecol. 1984;64:708. - PubMed
    1. Berek JS, Hacker NF, Lichtenstein A, Jung T, Spina C, Knox RM, Brady J, Greene T, Ettinger LM, Lagasse LD, Bonnem EM, Spiegel RJ, Zighelboim J. Intraperitoneal recombinant α-interferon for “Salvage” immunotherapy in salvage III epithelial ovarian cancer: A Gynecologic Oncology Group Study. Cancer Res. 1985;45:4447. - PubMed

Publication types

LinkOut - more resources